Dog Mast Cell Tumour Grade III: Welfare and Treatment

High-grade mast cell tumours in dogs are aggressive malignancies requiring urgent, comprehensive treatment and presenting significant welfare challenges during diagnosis and therapy.

Key Facts

Mast cell tumours are the most common skin tumour in dogs, with grades ranging from I (benign) to III (aggressive)
Grade III tumours metastasise to lymph nodes, spleen, liver, and bone marrow in most cases
Treatment typically involves surgery, chemotherapy, and potentially radiation therapy
Targeted therapy with tyrosine kinase inhibitors (masitinib, toceranib) has improved outcomes for KIT-mutated tumours
Median survival for high-grade MCT without treatment is weeks; with aggressive treatment, months to years

Welfare Considerations

High-grade mast cell tumours cause welfare challenges both from the tumour itself and from treatment. Tumours can release histamine causing systemic effects including gastrointestinal ulceration, hypotension, and local oedema. Chemotherapy causes temporary side effects including nausea and immunosuppression. The welfare-centred approach requires honest discussion of prognosis, realistic assessment of treatment burden versus benefit, and quality of life monitoring throughout therapy. For some dogs, palliative care focused on comfort rather than cure may be the most welfare-appropriate choice when aggressive treatment is not feasible or desired.

What You Can Do

Seek veterinary oncologist assessment promptly for any skin lump identified as a mast cell tumour
Request histopathological grading and KIT mutation testing to guide treatment choice
Monitor dogs on chemotherapy closely for side effects and adjust treatment if quality of life is significantly impaired
Discuss palliative care options with your veterinarian if aggressive treatment is not appropriate